Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aging
Scientists at Institute on Aging, Department of Geriatrics publish research in aging
June 26th, 2007
Investigators publish new data in the report "Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Peroxisome proliferator-activated receptor-gamma (PPARgamma) regulates both glucose metabolism and bone mass. Recent evidence suggests that the therapeutic modulation of PPARgamma activity with antidiabetic thiazolidinediones elicits unwanted effects on bone," scientists in the United States report. "In this study, the effects of rosiglitazone on the skeleton of growing (1 month), adult (6 month), and aged (24 month) C57BL/6 mice were determined. Aging was identified as a confounding factor for rosiglitazone-induced bone loss that...
Source: Drug Law Weekly (2007-06-26)
|
